

If you are in any doubt as to any aspect of this circular or as to the action to be taken, you should consult your stockbroker or other licensed securities dealer, bank manager, solicitor, professional accountant or other professional adviser.

If you have sold or transferred all your shares in Beijing Chunlizhengda Medical Instruments Co., Ltd.* (北京市春立正達醫療器械股份有限公司), you should at once hand this circular to the purchaser or transferee or to the bank or stockbroker or other licensed securities dealer or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.



北京市春立正達醫療器械股份有限公司
Beijing Chunlizhengda Medical Instruments Co., Ltd.*
(A joint stock limited company incorporated in the People's Republic of China with limited liability)
(Stock Code: 1858)

2022 PROFIT DISTRIBUTION PLAN
APPOINTMENT OF AUDITORS (DOMESTIC AND OVERSEAS) AND
INTERNAL CONTROL AUDITOR FOR 2023
REMUNERATION FOR DIRECTORS OF THE COMPANY FOR 2023
ANNUAL REPORT FOR THE YEAR 2022 AND ITS SUMMARY
FINANCIAL REPORT FOR THE YEAR 2022
2022 PERFORMANCE REPORT OF THE INDEPENDENT NON-EXECUTIVE
DIRECTORS
REPORT OF BOARD OF DIRECTORS FOR THE YEAR 2022
REMUNERATION FOR SUPERVISORS OF THE COMPANY FOR 2023
REPORT OF SUPERVISORS FOR THE YEAR 2022
PROPOSED RE-ELECTION AND APPOINTMENT OF DIRECTORS AND
SUPERVISORS
GRANTING THE GENERAL MANDATE TO THE BOARD TO REPURCHASE
H SHARES
NOTICE OF THE 2022 ANNUAL GENERAL MEETING AND
NOTICE OF H SHAREHOLDERS' CLASS MEETING

The 2022 Annual General Meeting and Class Meetings will be held at 2:00 p.m., on Wednesday, 28 June 2023 at No. 10 Xinmi Xi Er Road, Southern District of Tongzhou Economic Development Zone, Tonghou District, Beijing, the PRC.

The forms of proxy for use at the 2022 Annual General Meeting and the H Shareholders' Class Meeting have been published on the website of the Hong Kong Stock Exchange (<http://www.hkexnews.hk>) and the website of the Company (<http://www.clzd.com>) on 28 May 2023. If you intend to appoint a proxy to attend the 2022 Annual General Meeting and/or the H Shareholders' Class Meeting, you are requested to complete and return the form of proxy in accordance with the instructions printed thereon not less than 24 hours before the time fixed for holding the 2022 Annual General Meeting and/or the H Shareholders' Class Meeting or any adjournment thereof (as the case may be). Completion and return of the form of proxy will not preclude you from attending the 2022 Annual General Meeting and/or the H Shareholders' Class Meeting and voting in person if you so wish.

CONTENTS

	<i>Page</i>
DEFINITIONS	1
LETTER FROM THE BOARD	4
APPENDIX I — REMUNERATION PLAN FOR THE DIRECTORS FOR 2023	13
APPENDIX II — 2022 PERFORMANCE REPORT OF THE INDEPENDENT NON-EXECUTIVE DIRECTORS	14
APPENDIX III — REMUNERATION PLAN FOR THE SUPERVISORS FOR 2023	21
APPENDIX IV — BIOGRAPHICAL DETAILS OF DIRECTORS AND SUPERVISORS PROPOSED TO BE RE-ELECTED AND APPOINTMENT AT THE AGM	22
APPENDIX V — EXPLANATORY STATEMENT	27
NOTICE OF 2022 ANNUAL GENERAL MEETING	31
NOTICE OF H SHAREHOLDERS' CLASS MEETING	35

DEFINITIONS

Unless the context otherwise requires, the following expressions in this circular shall have the following meanings:

“2022 Annual General Meeting”	the annual general meeting of the Company to be held at 2:00 p.m., on Wednesday, 28 June 2023 at No. 10 Xinmi Xi Er Road, Southern District of Tongzhou Economic Development Zone, Tonghou, District, Beijing, the PRC
“A Share(s)”	the ordinary share(s) issued by the Company, with a nominal value of RMB1.00 each, which are subscribed for or credited as paid in RMB and are listed for trading on the STAR Market of Shanghai Stock Exchange
“A Shareholder(s)”	the holder(s) of A Share(s)
“A Shareholders’ Class Meeting”	the A Shareholders’ class meeting of the Company to be held at 2:00 p.m. (or the time immediately after the conclusion of the 2022 Annual General Meeting) on Wednesday, 28 June 2023
“Articles of Association”	the articles of association of the Company currently in force
“Board” or “Board of Directors”	the board of Directors of the Company
“Board of Supervisors”	the board of Supervisors of the Company
“Class Meetings”	the A Shareholders’ Class Meeting and the H Shareholders’ Class Meeting
“Company”	Beijing Chunlizhengda Medical Instruments Co., Ltd.* (北京市春立正達醫療器械股份有限公司), a joint stock limited company incorporated in the People’s Republic of China with limited liability, the A Shares of which are listed on the STAR Market of Shanghai Stock Exchange (stock code: 688236) and the H Shares of which are listed on the Hong Kong Stock Exchange (stock code: 1858)
“CSRC”	China Securities Regulatory Commission
“Director(s)”	director(s) of the Company

DEFINITIONS

“H Share(s)”	ordinary share(s) of the Company, with a nominal value of RMB1.00 each, which are listed on the Hong Kong Stock Exchange and traded in Hong Kong dollars
“H Shareholder(s)”	the holder(s) of H Shares
“H Shareholders’ Class Meeting”	the H Shareholders’ class meeting of the Company to be held at 2:00 p.m. (or the time immediately after the conclusion of the A Shareholders’ Class Meeting) on Wednesday, 28 June 2023
“HK\$”	Hong Kong dollars, the lawful currency of Hong Kong
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
“Hong Kong Listing Rules”	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited
“Hong Kong Stock Exchange”	The Stock Exchange of Hong Kong Limited
“Latest Practicable Date”	25 May 2023, being the latest practicable date prior to the printing of this circular for ascertaining certain information contained in this circular
“PRC” or “China”	the People’s Republic of China, but for the purposes of this circular only, excludes Hong Kong, the Macau Special Administrative Region of the PRC and Taiwan
“Repurchase Mandate”	the general mandate to be granted to the Board at the 2022 Annual General Meeting and Class Meetings to exercise the power of the Company to repurchase H Shares not exceeding 10% of the total number of the H Shares in issue at the time when the relevant resolution proposed for granting such mandate for repurchasing H Shares is passed at the 2022 Annual General Meeting, the Class Meetings, respectively
“RMB”	Renminbi, the lawful currency of the PRC
“Securities and Futures Ordinance”	Securities and Futures Ordinance, Chapter 571 of the Laws of Hong Kong, as amended from time to time
“Shareholders”	holders of the Company’s Share(s)

DEFINITIONS

“Shares” ordinary share(s) of RMB1.00 each in the share capital of the Company

“SSE” the Shanghai Stock Exchange

“Supervisor(s)” supervisor(s) of the Company

* *For identification purposes only*

LETTER FROM THE BOARD



北京市春立正達醫療器械股份有限公司
Beijing Chunlizhengda Medical Instruments Co., Ltd.*

(A joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1858)

Executive Directors:

Ms. Shi Wenling (*Chairman*)

Mr. Shi Chunbao

Ms. Yue Shujun

Mr. Xie Feng Bao

Non-Executive Director:

Mr. Wang Xin

Independent Non-executive Directors:

Mr. Ge Changyin

Mr. Wong Tak Shing

Mr. Weng Jie

*Registered Office and Headquarters
in the PRC:*

No. 10 Xinmi Xi Er Road
Southern District of Tongzhou
Economic Development Zone
Tongzhou District
Beijing
the PRC
Postal Code: 101112

*Principal Place of Business
in Hong Kong:*

20th Floor, Winbase Centre
208 Queen's Road Central
Sheung Wan
Hong Kong

To the Shareholders

Dear Sir or Madam,

**2022 PROFIT DISTRIBUTION PLAN
APPOINTMENT OF AUDITORS (DOMESTIC AND OVERSEAS) AND
INTERNAL CONTROL AUDITOR FOR 2023
REMUNERATION FOR DIRECTORS OF THE COMPANY FOR 2023
ANNUAL REPORT FOR THE YEAR 2022 AND ITS SUMMARY
FINANCIAL REPORT FOR THE YEAR 2022
2022 PERFORMANCE REPORT OF THE INDEPENDENT NON-EXECUTIVE
DIRECTORS
REPORT OF BOARD OF DIRECTORS FOR THE YEAR 2022
REMUNERATION FOR SUPERVISORS OF THE COMPANY FOR 2023
REPORT OF SUPERVISORS FOR THE YEAR 2022
PROPOSED RE-ELECTION AND APPOINTMENT OF DIRECTORS AND
SUPERVISORS
GRANTING THE GENERAL MANDATE TO THE BOARD TO REPURCHASE
H SHARES
NOTICE OF THE 2022 ANNUAL GENERAL MEETING AND
NOTICE OF H SHAREHOLDERS' CLASS MEETING**

LETTER FROM THE BOARD

INTRODUCTION

The purpose of this circular is to give you notice of the 2022 Annual General Meeting and the Class Meetings and to provide you with information reasonably necessary to enable you to make an informed decision on whether to vote for or against the resolutions to be proposed at the 2022 Annual General Meeting and/or the Class Meetings (where applicable), which includes, among other things:

- (1) consider and approve the proposed profit distribution plan for 2022;
- (2) consider and approve the appointment of auditors (domestic and overseas) and internal control auditor for 2023;
- (3) consider and approve the remuneration for Directors of the Company for 2023;
- (4) consider and approve the annual report for the year 2022 and its summary;
- (5) consider and approve the financial report for the year 2022;
- (6) consider and approve the 2022 performance report of the independent non-executive Directors;
- (7) consider and approve the report of the Board of Directors for the year 2022;
- (8) consider and approve the remuneration for Supervisors of the Company for 2023;
- (9) consider and approve the report of Supervisors for the year 2022;
- (10) consider and approve the re-election and appointment of Directors and Supervisors; and
- (11) consider and approve the grant of the general mandate to the Board of Directors to repurchase the H Shares of the Company.

The item (11) as mentioned above are required to be proposed at the 2022 Annual General Meeting and Class Meetings for consideration in the form of special resolutions.

PROFIT DISTRIBUTION PLAN FOR 2022

An ordinary resolution will be proposed at the 2022 Annual General Meeting to consider and approve the 2022 Profit Distribution Plan of the Company.

As audited by WUYIGE Certified Public Accountants LLP (大信會計師事務所(特殊普通合夥)), the Company's audited consolidated net profit attributable to the owners of the parent company for 2022 was approximately RMB307.72 million. The actual profit

LETTER FROM THE BOARD

available for distribution in 2022 was approximately RMB298.78 million. The Board of Directors reviewed and approved the Profits Distribution Plan for 2022 of the Company on 30 March 2023.

According to the Profits Distribution Plan of the Company, the dividend for 2022 is proposed to be distributed to all Shareholders in cash at RMB3.13 per 10 Shares (tax inclusive) by the Company. In particular: A Shareholders will be paid in RMB; H Shareholders will be paid in HK dollars. The exchange rate of HK dollars will be calculated in accordance with the average closing price for foreign exchange published by the People's Bank of China at the seven working days prior to the date on which the dividend is declared. As at 31 December 2022, the total issued shares of the Company is 384,280,000. The Company repurchased a total of 711,500 H Shares on the Hong Kong Stock Exchange during the year ended 31 December 2022. Upon the cancellation of the repurchased H Shares, the total issued shares of the Company will be reduced to 383,568,500 Shares and a total cash dividend of RMB120,056,940 (tax inclusive) will be distributed, accounting for 39.02% of the net profit attributable to the owners of the parent company in the consolidated statements of the Company for 2022.

The dividend for 2022 is expected to be paid on or before 31 July 2023 to Shareholders whose names appear on the register of members of the Company as at 3 July 2023 in respect of H Shares.

If the total share capital of the Company changes before the record date(s) for the implementation of the profit distribution, the Company intends to maintain the distribution amount per Share unchanged and adjust the total distribution amount accordingly.

WITHHOLDING AND PAYMENT OF DIVIDEND TAX

In accordance with the Enterprise Income Tax Law of the People's Republic of China (《中華人民共和國企業所得稅法》) and its implementation rules effective on 1 January 2008, where a PRC domestic enterprise distributes dividends for financial periods beginning from 1 January 2008 to non-resident enterprise shareholders, it is required to withhold 10% enterprise income tax for such non-resident enterprise shareholders. Therefore, the Company will, after withholding 10% of the final dividend as enterprise income tax, distribute the final dividend to non-resident enterprise shareholders, i.e. any shareholders who hold the Company's shares in the name of non-individual shareholders, including but not limited to HKSCC Nominees Limited, other nominees, trustees, or holders of H Shares registered in the name of other organizations and groups.

According to regulations by the State Administration of Taxation (Guo Shui Han [2011] No. 348) (《國家稅務總局國稅函[2011]348號》) and relevant laws and regulations, if the individual holders of H shares are residents of Hong Kong or Macau or those countries which have entered into a tax treaty with the PRC stipulating a dividend tax rate of 10%, the Company will withhold and pay individual income tax at the rate of 10% on behalf of these shareholders. However, if otherwise provided by tax laws, relevant tax treaties or notices, the tax will be withheld in accordance with the relevant requirements and tax levy and administration requirements.

LETTER FROM THE BOARD

According to the requirements of the Notice on the Tax Policies Concerning the Pilot Program of the Shanghai-Hong Kong Stock Connect published by the Ministry of Finance, the State Administration of Taxation and the CSRC (Cai Shui [2014] No. 81) (《財政部、國家稅務總局、中國證監會關於滬港股票市場交易互聯互通機制試點有關稅收政策的通知》(財稅[2014]81號)), H-share companies shall withhold an individual income tax at the rate of 20% on dividends from the H shares of the company invested by mainland individual investors on the Hong Kong Stock Exchange through the Shanghai-Hong Kong Stock Connect. For dividends of the shares listed on the Hong Kong Stock Exchange received by mainland securities investment funds from investment through the Shanghai-Hong Kong Stock Connect, individual income tax shall be calculated in accordance with the above requirements. For dividends of the shares listed on the Hong Kong Stock Exchange received by mainland enterprise investors from investment through the Shanghai-Hong Kong Stock Connect, H-share companies shall not withhold income tax of dividends, and mainland enterprise investors shall report and pay the tax amount by themselves. In particular, the dividends received by resident enterprises in mainland which hold H shares for at least 12 consecutive months shall be exempted from enterprise income tax according to law.

According to the requirements of the Notice on the Tax Policies Concerning the Pilot Program of the Shenzhen-Hong Kong Stock Connect published by the Ministry of Finance, the State Administration of Taxation and the CSRC (Cai Shui [2016] No. 127) (《財政部、國家稅務總局、中國證監會關於深港股票市場交易互聯互通機制試點有關稅收政策的通知》(財稅[2016]127號)), H-share companies shall withhold an individual income tax at the rate of 20% on dividends from the H shares of the company invested by mainland individual investors on the Hong Kong Stock Exchange through the Shenzhen-Hong Kong Stock Connect. For dividends of the shares listed on the Hong Kong Stock Exchange received by mainland securities investment funds from investment through the Shenzhen-Hong Kong Stock Connect, individual income tax shall be calculated in accordance with the above requirements. For dividends of the shares listed on the Hong Kong Stock Exchange received by mainland enterprise investors from investment through the Shenzhen-Hong Kong Stock Connect, H-share companies shall not withhold income tax of dividends, and mainland enterprise investors shall report and pay the tax amount by themselves. In particular, the dividends received by resident enterprises in mainland which hold H shares for at least 12 consecutive months could be exempted from enterprise income tax according to law.

APPOINTMENT OF AUDITORS (DOMESTIC AND OVERSEAS) AND INTERNAL CONTROL AUDITORS FOR 2023

An ordinary resolution will be proposed at the 2022 Annual General Meeting to consider and approve the appointment of WUYIGE Certified Public Accountants LLP (大信會計師事務所(特殊普通合夥)) as the domestic auditor and overseas auditor of the Company's financial report for 2023, until the conclusion of the Company's 2023 annual general meeting, and that the Board be authorized to fix its remuneration.

According to the Basic Standards of Enterprise Internal Control (《企業內部控制基本規範》) and the Ancillary Guidance on Enterprise Internal Control (《企業內部控制配套指引》) and the information disclosure requirements for listed companies on the STAR

LETTER FROM THE BOARD

Market of Shanghai Stock Exchange, the Company is required to appoint a qualified accounting firm to conduct annual audit on its internal control and disclose the underlying audit report since 2020. The Board proposed that WUYIGE Certified Public Accountants LLP (大信會計師事務所(特殊普通合夥)) be appointed as the internal control auditor for 2023, until the Company's 2023 annual general meeting, and that the Board be authorized to fix its remuneration.

REMUNERATION FOR DIRECTORS OF THE COMPANY FOR 2023

An ordinary resolution will be proposed at the 2022 Annual General Meeting to consider and approve the remuneration for Directors of the Company for 2023.

In accordance with the current economic environment, the regions of operations of the Company, industry and scale of the Company and with reference to remuneration of the industry, the Company has formulated the Remuneration Plan for the Directors for 2023, which is set out in Appendix I to this circular.

ANNUAL REPORT FOR THE YEAR 2022 AND ITS SUMMARY

An ordinary resolution will be proposed at the 2022 Annual General Meeting to approve the Company's 2022 annual report and its summary. Please refer to the Company's annual report for the year 2022 published on the websites of the Hong Kong Stock Exchange and the Company on 27 April 2023.

FINANCIAL REPORT FOR THE YEAR 2022

An ordinary resolution will be proposed at the 2022 Annual General Meeting to approve the financial report for the year 2022. The audited financial statements prepared in compliance with the China Accounting Standards and the auditor's report for the year 2022 have been set out in the Company's 2022 annual report.

2022 PERFORMANCE REPORT OF THE INDEPENDENT NON-EXECUTIVE DIRECTORS

An ordinary resolution will be proposed at the 2022 Annual General Meeting to approve the 2022 performance report of the independent non-executive Directors.

The full text of the performance report of the independent non-executive Directors is set out in Appendix II of this circular.

REPORT OF THE BOARD OF DIRECTORS FOR THE YEAR 2022

An ordinary resolution will be proposed at the 2022 Annual General Meeting to approve the report of the Board of Directors for the year 2022. Please refer to the report of the Board of Directors as set out in the Company's annual report for the year 2022.

REMUNERATION FOR SUPERVISORS OF THE COMPANY FOR 2023

An ordinary resolution will be proposed at the 2022 Annual General Meeting to consider and approve the remuneration for Supervisors of the Company for 2023.

LETTER FROM THE BOARD

In accordance with the relevant laws and regulations, requirements of regulatory documents, and the Articles of Association, together with the remuneration levels of the operation industries and regions of the Company, the annual operating condition and job responsibilities, the Company has formulated the Remuneration Plan for the Supervisors for 2023, which is set out in Appendix III to this circular.

REPORT OF THE BOARD OF SUPERVISORS FOR THE YEAR 2022

An ordinary resolution will be proposed at the 2022 Annual General Meeting to approve the report of the Board of Supervisors for the year 2022. Please refer to the report of the Board of Supervisors as set out in the Company's annual report for the year 2022.

PROPOSED RE-ELECTION AND APPOINTMENT OF DIRECTORS AND SUPERVISORS

An ordinary resolution will be proposed at the 2022 Annual General Meeting to approve the re-election and appointment of Directors and Supervisors of the Company.

Reference is made to the announcement of the Company dated 30 March 2023 in relation to, among others, the proposed re-election and appointment of Directors and Supervisors. Within the members of the fourth session of the Board, except for Mr. Ge Changyin (independent non-executive Director) who will step down and no longer participate in the re-election for Directors of the fifth session of the Board, the other seven Directors of the fourth session of the Board confirmed that they will participate in the re-election of Directors at the 2022 Annual General Meeting. Within the members of the fourth session of the Supervisory Committee (save for the employee-elected Supervisors), Mr. Zhang Jie, a Supervisor of the fourth session of the Supervisory Committee, has confirmed that he will participate in the re-election of Supervisors at the general meeting of the Company.

To the best of the knowledge and belief of the Board and the Supervisory Committee having made all reasonable inquiries, regarding the Directors and Supervisors soon to step down, they have no disagreement with the Board and the Supervisory Committee, and there are no matters need to be brought to the attention of the Shareholders.

Save for the resolutions for re-election of Directors and Supervisors, the Board has proposed to appoint Ms. Yao Lijie as an independent non-executive Director of the Company to form the fifth session of the Board.

The terms of office of the above Directors and Supervisors will be three years, with effect from consideration and approval of such resolutions at the 2022 Annual General Meeting. The above Directors and Supervisors will receive a remuneration in accordance with the remuneration proposal, which will be determined with reference to his/her duties and responsibilities with the Company and the actual situation of the Company, and will be subject to the consideration at the 2022 Annual General Meeting.

LETTER FROM THE BOARD

To enable the Shareholders to make an informed decision on the re-election and appointment of these Directors and Supervisors, the biographical details of the Directors and Supervisors who are subject to re-election and appointment at the 2022 Annual General Meeting, as required under Chapter 13 of the Hong Kong Listing Rules, are set out in the Appendix IV of this circular.

GRANTING THE GENERAL MANDATE TO THE BOARD OF DIRECTORS TO REPURCHASE H SHARES

A special resolution will be proposed at the 2022 Annual General Meeting and the Class Meetings to consider and approve the proposal on granting the general mandate to the Board to repurchase H Shares of the Company.

It is proposed that a general mandate be granted to the Board to repurchase H Shares of the Company not exceeding 10% of its total number of the H Shares in issue when the Repurchase Mandate is approved at the 2022 Annual General Meeting and the Class Meetings with reference to market conditions, funding arrangements and the needs of the Company and in accordance with the relevant laws and regulations, the Articles of Association, requirements of securities regulatory authorities of the places where the shares of the Company are listed and any other relevant government or regulatory authorities in the PRC when the Board believes that such repurchase is beneficial to the Company and the Shareholders as a whole.

It is proposed that the authorization granted to the Board by the 2022 Annual General Meeting and the Class Meetings includes but not limited to:

- i) formulating and implementing specific repurchase plan, including but not limited to repurchase price(s), number of H Shares to be repurchased, timing(s) of repurchase and period(s) of repurchase, etc;
- ii) notifying creditors and making announcement(s) in accordance with the requirements of the Company Law of the PRC, other laws and regulations and the Articles of Association;
- iii) opening overseas stock accounts, capital accounts and carrying out relevant procedures of change in foreign exchange registration;
- iv) carrying out relevant approval, filing and/or disclosure procedures (if necessary) in accordance with laws, regulations, the Articles of Association and requirements of the securities regulatory authorities of the places where the shares of the Company are listed and any other relevant government or regulatory authorities in the PRC;
- v) carrying out the cancellation procedure of the repurchased H Shares, reducing the registered capital of the Company, amending the Articles of Association in relation to the total amount of share capital, share capital structure and other relevant contents and carrying out the legal registration and filing procedures in the PRC and overseas; and
- vi) executing all documents and dealing with other matters in relation to the repurchase of H Shares.

LETTER FROM THE BOARD

The General Mandate will expire on the earlier of:

- (a) the conclusion of the annual general meeting of the Company for the year 2023; or
- (b) the date on which the authorization granted by the relevant special resolution is revoked or varied by a special resolution at the general meeting, the class meeting of the holders of H Shares and the class meeting of the holders of A Shares of the Company (the “**Relevant Period**”).

The Explanatory Statement of the Repurchase Mandate is set out in Appendix V to this circular, which contains further details of the Repurchase Mandate.

2022 ANNUAL GENERAL MEETING AND CLASS MEETING

The 2022 Annual General Meeting, A Shareholders’ Class Meeting and H Shareholders’ Class Meeting of the Company will be held at 2:00 p.m., immediately after the conclusion of the 2022 Annual General Meeting and immediately after the conclusion of the A Shareholders’ Class Meeting, respectively, on Wednesday, 28 June 2023 at No. 10 Xinmi Xi Er Road, Southern District of Tongzhou Economic Development Zone, Tongzhou, District, Beijing. The notice to convene the 2022 Annual General Meeting and notice to convene the H Shareholders’ Class Meeting have been published on 28 May 2023 and are set out on pages 31 to 34 and 35 to 37 of this circular respectively and the forms of proxy for use at the 2022 Annual General Meeting and H Shareholders’ Class Meeting are also enclosed hereto.

In order to be qualified to attend and vote at the 2022 Annual General Meeting and the H Shareholders’ Class Meeting, holders of H Shares whose transfers have not been registered must deposit the transfer documents together with the relevant share certificates at the office of the H Share registrar of the Company, Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong by no later than 4:30 p.m. on Wednesday, 21 June 2023.

Holders of H Shares whose names appear on the Company’s register of members at the close of business on Wednesday, 21 June 2023 are entitled to attend and vote at the 2022 Annual General Meeting and the H Shareholders’ Class Meeting.

The forms of proxy for use at the 2022 Annual General Meeting and H Shareholders’ Class Meeting have been published on the website of the Hong Kong Stock Exchange (<http://www.hkexnews.hk>) and the website of the Company (<http://www.clzd.com>) on 28 May 2023. If you intend to appoint a proxy to attend the 2022 Annual General Meeting and/or H Shareholders’ Class Meeting, you are requested to complete and return the form of proxy in accordance with the instructions printed thereon not less than 24 hours before the time fixed for holding the 2022 Annual General Meeting and/or the H Shareholders’ Class Meeting or any adjournment thereof (as the case may be). Completion and return of the form of proxy will not preclude you from attending the 2022 Annual General Meeting and/or the H Shareholders’ Class Meeting and voting in person if you so wish.

LETTER FROM THE BOARD

As Mr. Shi Chunbao and Ms. Yue Shujun are controlling shareholders (as defined in the Listing Rules) and executive Directors of the Company, Mr. Shi Chunbao and Ms. Yue Shujun will abstain from voting on the relevant resolution in relation to the Remuneration Plan for the Directors for 2022. Save as mentioned above, as at the Latest Practicable Date, and to the best knowledge, belief and information of the Directors having made all reasonable enquiries, no Shareholder is required under the Listing Rules to abstain from voting on the proposed resolutions at the 2022 Annual General Meeting and the H Shareholders' Class Meeting.

PROCEDURES FOR VOTING AT THE 2022 ANNUAL GENERAL MEETING AND CLASS MEETING

According to Rule 13.39(4) of the Hong Kong Listing Rules, the vote of Shareholders at the 2022 Annual General Meeting will be taken by poll. Accordingly, all the resolutions could be taken by poll at the 2022 Annual General Meeting and the Class Meetings pursuant to the Articles of Association.

RESPONSIBILITY STATEMENT

This circular, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief, the information contained in this circular is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this circular misleading.

RECOMMENDATION

As Mr. Shi Chunbao and Ms. Yue Shujun are controlling shareholders (as defined in the Listing Rules) and executive Directors of the Company, Mr. Shi Chunbao and Ms. Yue Shujun have abstained from voting on the relevant Board resolution in relation to the Remuneration Plan for the Directors for 2022. Save as mentioned above, none of the Directors has any material interest in the resolutions to be proposed at the 2022 Annual General Meeting and the H Shareholders' Class Meeting. The Directors believe that the proposals mentioned above are in the best interests of the Company and the Shareholders as a whole. Accordingly, the Directors recommend that Shareholders vote in favour of the resolutions to be proposed at the 2022 Annual General Meeting and/or the Class Meetings as set out in the notices of the 2022 Annual General Meeting and/or the Class Meetings.

By order of the Board
Beijing Chunlizhengda Medical Instruments Co., Ltd.*
Shi Wenling
Chairman

Beijing, the PRC
29 May 2023

* For identification purposes only

BEIJING CHUNLIZHENGDA MEDICAL INSTRUMENTS CO., LTD.*

REMUNERATION PLAN OF THE DIRECTORS FOR 2023

Dear Shareholders,

In accordance with the current economic environment, the regions of operations of the Company, industry and scale of the Company and with reference to remuneration of the industry, the Company has formulated the Remuneration Plan for the Directors for 2023.

i. Remuneration of executive Directors

Executive Directors are remunerated according to their performance appraisal in accordance with the specific management positions they hold in the Group and are no longer separately remunerated as Directors. The specific remuneration of the executive Directors will be considered by the Board.

ii. Remuneration of non-executive Directors (including independent non-executive Directors)

Non-executive Directors (including independent non-executive Directors), of which Mr. Wang Xin, a non-executive Director, Ms. Yao Lijie and Mr. Weng Jie, independent non-executive Directors, are remunerated at a fixed rate of RMB100,000/year (before tax) and Mr. Wong Tak Shing, an independent non-executive Director, is remunerated at a fixed rate of RMB175,800/year (before tax).

* For identification purposes only

BEIJING CHUNLIZHENGDA MEDICAL INSTRUMENTS CO., LTD.*

2022 PERFORMANCE REPORT OF THE INDEPENDENT NON-EXECUTIVE
DIRECTORS

As Independent Non-executive Directors of Beijing Chunlizhengda Medical Instruments Co., Ltd. (hereinafter as the “Company”), we performed our duties as Independent Non-executive Directors diligently in 2022 in strict accordance with the Company Law of the People’s Republic of China (the “Company Law”), the Securities Law of the People’s Republic of China (hereinafter as the “Securities Law”), the Rules Governing the Listing of Stocks on the STAR Market of the Shanghai Stock Exchange, the Guidelines for Governance of Listed Companies, the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Articles of Association of Beijing Chunlizhengda Medical Instruments Co., Ltd. (hereinafter as the “Articles of Association”), the Working Systems for Independent Directors of Beijing Chunlizhengda Medical Instruments Co., Ltd. (hereinafter as the “Working Systems”) and other laws and regulations, regulatory documents, company system requirements. We have safeguarded the legitimate interests of all shareholders and fully capitalized on the effectiveness of Independent Non-executive Directors. The duty performance as Independent Non-executive Directors in 2022 is hereby reported as follows:

1. INDEPENDENCE

As Independent Non-executive Directors, we are in no relationship with the Company and the substantial shareholders, directors, supervisors and senior management of the Company which interferes with our exercise of independent and objective judgment, have not been appointed in related enterprises of the Company, have met the requirements of independence in relevant laws and regulations, have adhered to objective and independent professional judgments in the performance of our duties, and safeguarded the interests of all shareholders, especially small and medium investors.

* For identification purposes only

2. ANNUAL DUTY PERFORMANCE OF INDEPENDENT NON-EXECUTIVE DIRECTORS**(1) Attendance at Meetings**

For the year 2022, the Company convened 4 general meetings, 15 board meetings, 5 meetings of the Audit Committee, 2 meetings of the Nomination Committee, 2 meetings of the Remuneration Committee and 2 meetings of the Strategy Committee in total. In 2022, we attended the general meetings, board meetings and meetings of special committees as follows:

Name of Independent Director	Number of General Meetings Attended	Number of Board Meeting Attended	Number of Meeting of the Audit Committee Attended	Number of Meeting of the Nomination Committee Attended	Number of Meeting of the Remuneration Committee Attended	Number of Meeting of the Strategy Committee Attended
Ge Changyin	4	15	5	2	2	–
Weng Jie	4	15	5	2	2	–
Wong Tak Shing	4	15	5	–	–	–

During the reporting period, as Independent Non-executive Directors of the Company, we have actively participated in the board meetings and general meetings of the Company and faithfully performed the duties as Independent Non-executive Directors. Before attending the meetings, we carefully reviewed the meeting materials, fully communicated with the Company's management, actively discussed each proposal, and carefully reviewed each proposal in the board meetings of the Company. We used our own professional knowledge to exercise voting rights independently, objectively and prudently, and expressed independent opinions. No objection was raised to any of the proposals.

(2) On-site inspection and the Company's cooperation with Independent Directors in their work

Affected by the pandemic, in 2022, we mainly maintained close contact with the Company's management, secretary to the Board and relevant staff through telephone, email, online meetings, etc. to communicate regularly and understand the Company's daily operations. During the reporting period, the Company actively cooperated with our work to provide convenience for us to perform the duties of independent directors, actively participated in training, continuously improving our ability to perform duties.

3. KEY ISSUES OF CONCERN REGARDING ANNUAL DUTY PERFORMANCE OF INDEPENDENT NON-EXECUTIVE DIRECTORS

During the year, we focused on the reviewing the following issues of the Company in accordance with the requirements in relation to the functions and powers of the independent non-executive directors under the Company Law, the Securities Law and other laws and regulations and the Articles of Association.

(1) Related Party (Connected) Transactions

During the reporting period, the daily transactions between the Company and the related parties constituted normal business activities, which supported the Company's production, operation and sustainable development to a certain extent, and was conducive to the stability of the Company's normal operation. The Company and the related parties remain independent, and the Company's principal business will not rely on the related parties for such transactions. The Company's daily connected transactions followed the principles of openness, fairness and impartiality, were negotiated and priced with reference to the market price, which will not harm the interests of the Company and all shareholders, especially small and medium shareholders. The transaction procedures are in compliance with laws and regulations and the Articles of Association.

(2) External Guarantees and Fund Occupation

During the reporting period, as Independent Non-executive Directors of the Company, we have reviewed the Company's external guarantees. The Company strictly followed the Articles of Association and relevant regulations of the Company, and no external guarantees occurred during the reporting period. During the reporting period, there was no non-operating fund occupation of the Company by the related (connected) parties.

(3) Use of Raised Proceeds

According to the Regulatory Guidance No. 2 of Listed Companies — Supervision and Administration Requirements for Listed Companies on the Management and Use of Raised Funds (2022 Revision) (CSRC Announcement No. 15 [2022]), Shanghai Stock Exchange STAR Market Guidelines No. 1 for Self-Regulation for Listed Companies – Standard Operation and the management system for raised proceeds of the Company and other relevant regulations, the Independent Directors have reviewed the deposit and actual use of proceeds of the Company in 2022. The management and use of proceeds of the Company do not change the use of proceeds in disguised form and damage the interests of the shareholders of the Company, especially small and medium shareholders, which is in line with the needs of the Company's development interests, conducive to improving the efficiency of the Company's use of proceeds and obtaining good investment returns, and is in the interests and long-term interests of the shareholders as a whole. During the Reporting Period, the use of proceeds of the Company was consistent with the disclosed contents.

(4) Mergers and Acquisitions

During the Reporting Period, the Company did not have any mergers and acquisitions.

(5) Nomination and Remuneration of Directors and Senior Management

During the Reporting Period, we expressed independent opinions for approval on the remuneration plan for the directors and senior management of the Company for 2022. We are of the view that the remuneration of the directors and senior management of the Company has fulfilled the approval procedures in accordance with the relevant provisions of the Company Law, the Articles of Association and the Procedure Rules for Remuneration Committee under the Board of Directors of the Company, taking into full consideration the operating conditions of the Company's operation and the remuneration level in the industry, which is in line with the development stage of the Company and is conducive to the stable operation and development of the Company, and does not prejudice the interests of the Company and the Shareholders.

(6) Performance Bulletins

During the Reporting Period, the Company disclosed its annual preliminary results in accordance with the relevant requirements of the Rules Governing the Listing of Stocks on the STAR Market of the Shanghai Stock Exchange. The information disclosure was in compliance with the principles of truthfulness, accuracy, completeness, timeliness and fairness, and protected information rights and interests of investors.

(7) Engagement or Change of Accounting Firms

During the Reporting Period, we expressed independent opinions of prior approval and consent on the re-appointment of WUYIGE Certified Public Accountants LLP as the domestic and overseas audit institutions of the Company for 2022. We are of the view that WUYIGE Certified Public Accountants LLP possesses the relevant business qualifications, has extensive experience in audit business, and is capable of providing domestic and overseas audit-related services for the Company, without prejudice to the interests of the Company and its shareholders. The appointment procedures of the accounting firm are in compliance with the laws, regulations, regulatory documents and the Articles of Association.

(8) Cash Dividends and Other Investor Returns

On 30 March 2023, as considered and approved at the thirty-fifth meeting of the fourth session of the Board, based on the total share capital (excluding the shares in the securities account designated for the repurchase of H shares of the Company) registered on the record date for the implementation of the equity distribution, the profit distribution plan for 2022 is as follows: the Company intends to distribute cash dividends of RMB3.13 (tax inclusive) for every 10 shares to all shareholders. The total amount of cash

dividends to be distributed is RMB120,056,900 (tax inclusive), accounting for 39.02% of the net profit attributable to the shareholders of the listed company in 2022. We believe that the 2022 annual profit distribution plan of the Company has fully considered various factors such as the Company's actual operating results, cash flow and capital needs, without prejudice to the interests of shareholders, and will not affect the normal operation and long-term development of the Company. The decision-making procedures, distribution criteria and proportion of the resolution are clear and well-defined, and are in compliance with the Articles of Association and relevant approval procedures.

(9) Implementation of Commitments Made by the Company and Its Shareholders

In 2022, we paid attention to the implementation of commitments made by the Company and the relevant shareholders of the Company in relation to the non-competition, standardisation of related (connected) transactions, lock-up of shares, etc. All of the above-mentioned covenantors strictly complied with the commitments, and there was no breach of such commitments.

(10) Implementation of Information Disclosure

During the reporting period, the company provided investors with timely, accurate, true and complete information in strict accordance with the Rules Governing the Listing of Stocks on the STAR Market of the Shanghai Stock Exchange, the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and other relevant regulations as well as the Company's regulations on disclosure of information. There were no false records, misleading statements or material omissions. The disclosure objectively and fairly reflected the current operating conditions of the Company, helped investors to keep abreast of the Company's conditions in a timely manner, and safeguarded the interests of all shareholders of the Company.

(11) Implementation of Internal Control

During the reporting period, we assessed the appropriateness of the Company's internal control system and communicated with the external auditors on the effectiveness of the Company's internal control system. We believe that the Company strictly implemented various laws, regulations, rules and internal management systems, and the general meeting, the Board, the Supervisory Committee and the management operated in a standardised manner, which effectively protected the legitimate rights and interests of the Company and its shareholders. The actual operation of the Company's internal control was in compliance with the requirements on the corporate governance standards for listed companies issued by the CSRC, the Shanghai Stock Exchange and the Hong Kong Stock Exchange. There were no major deficiencies in internal control of financial reports or non-financial reports during the reporting period.

(12) Operation of the Board and Its Special Committees

There are four special committees under the Board of the Company: the Nomination Committee, the Audit Committee, the Remuneration Committee and the Strategy Committee. Independent non-executive directors in the Audit Committee, the Nomination Committee and the Remuneration Committee account for the majority and serve as the chairman. Please refer to “2. Annual Duty Performance of Independent Non-executive Directors — (1) Attendance at Meetings” in this report for details of the convening of the meetings of the Board and special committees of the Company and our attendance at such meetings during the reporting period. During the reporting period, the convening and holding procedures of the meetings of the Board and its special committees were in compliance with the relevant laws and regulations and the Articles of Association. The notice of the meeting and the meeting materials were delivered in a timely manner. The contents of the resolutions were true, accurate and complete. The voting procedures and the voting results were legal and valid. The Board and the special committees of the Company carried out their work in accordance with the relevant provisions of the working rules, fulfilled their duties and responsibilities, and provided reasonable suggestions for the Company’s internal governance and production and operation, which effectively improved the level of scientific decision-making of the Company.

(13) New Business Development

During the reporting period, the Company did not develop any new business.

(14) Other Matters Which Are Required by the Independent Non-executive Directors to be Improved

We believe that during the reporting period, the Company operated in a standardized manner, the corporate governance system was relatively complete, and there are no matters that need to be improved.

4. OVERALL EVALUATION AND RECOMMENDATIONS

In 2022, the Company’s directors, supervisors, senior management and related personnel have given strong support and cooperation to the Independent Directors in performing their duties, and we would like to express our sincere gratitude. As Independent Directors of the Company, we discharged our duties based on the principles of objectiveness, fairness and independence, with integrity and diligence, and in strict compliance with the relevant regulations such as the Company Law, the Securities Law, the Listing of Stocks on the STAR Market of the Shanghai Stock Exchange, the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, and the Articles of Association. Based on the principles of objectivity, impartiality and independence, perform duties with integrity and diligence. We carefully reviewed various meeting proposals, financial reports and other documents submitted by the Company, participated in the decision-making of material matters of the Company, fully capitalized on the effectiveness of Independent Non-executive Directors and safeguarded the interests of the Company and the legitimate rights of the shareholders (especially small and medium shareholders) as a whole.

In 2023, we will continue to uphold the principle of being accountable to all Shareholders in accordance with the requirements of relevant laws and regulations and the Articles of Association, maintain good communication with the Company's management, express opinions independently and objectively, and at the same time, make use of professional knowledge and experience to provide opinions and recommendations for the Company's development, and play an active role in continuously enhancing and improving the level of corporate governance and promoting the Company's stable operation.

Independent Non-executive Directors:
Ge Changyin, Weng Jie, Wong Tak Shing
31 March 2023

BEIJING CHUNLIZHENGDA MEDICAL INSTRUMENTS CO., LTD.*

REMUNERATION PLAN OF THE SUPERVISORS FOR 2023

Dear Shareholders,

According to the relevant laws and regulations, requirements of regulatory documents, and the Articles of Association, together with the remuneration levels of the operation industries and regions of the Company, the annual operating condition and job responsibilities, employee Supervisors are no longer separately remunerated as Supervisors and will be remunerated according to the performance of the Company, service agreements entered into with the Company and annual individual assessment.

The Remuneration Plan of the Supervisors for 2023 has been considered and adopted at the sixth meeting of the fourth session of the Board of Supervisors on 30 March 2023.

* For identification purposes only

The following is the personal biography of the director and supervisor candidates who were nominated to elect and appoint at the 2022 Annual General Meeting:

DIRECTORS

Executive Directors

Mr. Shi Chunbao (史春寶), aged 53, is our executive Director, chairman of the strategy committee of the Company and chief engineer. He is responsible for providing strategic advice and guidance on the business and operations of our Group. Mr. Shi became our Director in September 2010 and was redesignated as our executive Director on 16 April 2014. In February 1998, Mr. Shi together with his wife, Ms. Yue Shujun, established Chunli Limited. Mr. Shi was appointed as the general manager and a director of Chunli Limited in February 1998. Mr. Shi has been the chairman of the Board and the general manager of our Company since September 2010, as well as the sales and marketing director of our Company since December 2010. Mr. Shi has resigned as the chairman of the Board with effect from the appointment of a new chairman by the Board and has resigned as the general manager of the Company with effect from 28 March 2022. Prior to the establishment of the Group, Mr. Shi worked as a technician for plasma spraying in Beijing Peace Joint Prosthesis Factory (北京市和平人工關節廠) from 1991 to 1993, the principal business activities of which covered the production and sales of implantable orthopedic medical devices, and was responsible for the spraying of joint prosthesis products. He then worked as a sales representative at the sales department of the factory from 1993, and as the head of the sales department of the factory from 1995 to 1997, being responsible for the sales of joint prosthesis products. He gained access to and possessed knowledge and experience in the medical device industry from his aforesaid previous working experience.

Mr. Shi obtained a Master degree in Business Administration from Concordia University, Wisconsin, the USA in August 2010.

As at the Latest Practicable Date, Mr. Shi is deemed to be interested in 210,288,585 shares of the Company within the meaning of Part XV of the SFO.

Ms. Yue Shujun (岳術俊), aged 51, is our executive Director and deputy general manager. She is responsible for the internal operations of our Group, including logistics, inventory and day-to-day management. Ms. Yue became our Director in September 2010 and was redesignated as our executive Director in April 2014. In February 1998, Ms. Yue together with her husband, Mr. Shi Chunbao, established Chunli Limited. She held the position of administration manager of Chunli Limited from February 1998 to January 2001. Ms. Yue then held the position of manager of the sales and marketing department of Chunli Limited from February 2001 to October 2002, the manager of the finance department of Chunli Limited from November 2002 to August 2008, supervisor from February 1998 to September 2010 of Chunli Limited. She has been the deputy general manager of our Company since September 2010. Prior to the establishment of the Group, Ms. Yue worked in Beijing Peace Joint Prosthesis Factory (北京市和平人工關節廠) from

1994 to 1997, the principal business activities of which covered the production and sales of implantable orthopedic medical devices, and was responsible for the sales of joint prosthesis products. She gained access to and possessed knowledge and experience in the medical device industry from her aforesaid previous working experience.

Ms. Yue completed a course of Advanced Study in Modern Economics and Management (現代經濟管理高級研修班) at the School of Continuing Education at Tsinghua University, Beijing (清華大學) in September 2006 and a course of Master Financial Manager (高級財務經理人課程) at the School of Economics and Management at Tsinghua University, Beijing in September 2009. Ms. Yue obtained a certificate for Senior International Finance Manager (高級國際財務管理師) jointly awarded by the China Association of Chief Financial Officers (中國總會計師協會) and International Financial Management Association (國際財務管理協會) in April 2009.

As at the Latest Practicable Date, Ms. Yue is deemed to be interested in 210,288,585 shares of the Company within the meaning of Part XV of the SFO.

Ms. Shi Wenling (史文玲), aged 25, is our executive Director and chairman of our Board. Ms. Shi worked at the user expansion department of Beijing Bytedance Technology Co., Ltd.* (北京字節跳動科技有限公司) in 2021 and joined the Company in March 2022 as the assistant to the Chairman. Ms. Shi graduated from Ohio State University in United States of America with a double degree in marketing and operation management in 2020.

Ms. Shi is the daughter of Mr. Shi Chunbao, who is a controlling shareholder (as defined in the Listing Rules) and an executive Director of the Company and Ms. Yue Shujun, who is a controlling shareholder (as defined in the Listing Rules), deputy general manager and an executive Director of the Company.

Mr. Xie Feng Bao (解鳳寶), aged 40, is currently deputy chief engineer of the Company. His major responsibilities include participating in the formulation of the company's annual plan, the research and development of infrastructure for each department, and improving the research and development process and regulatory system. He is also involved in the coordination of the internal and external research and development projects of the Company and the application for national research and development projects. He joined the Company in March 2001 and worked as a research and development engineer until August 2009. He was a research and development manager of the Company from September 2009 to June 2019. He was promoted to his current role as deputy chief engineer in July 2019.

Mr. Xie graduated from China University of Geosciences (中國地質大學) majoring in mechanical engineering and automation (機械設計製造及其自動化).

Non-executive Director

Mr. Wang Xin (王鑫), aged 46, is currently non-executive Director of the Company. He participated in a number of experiments and clinical tasks for scientific research, and won third-class merit citation for two times, outstanding medical practitioner for 5 times, and provincial technological advancement award for 6 times. He was the resident doctor, doctor-in-charge, deputy chief doctor and chief doctor consecutively of the Department of Orthopaedics of the Urumqi General Hospital of Lanzhou Military Region from July 1999 to March 2017. He was the chief doctor of the Institute of orthopedics, PLA General Hospital from April 2017 to May 2018. Mr. Wang has been a full-time expert of Far East Horizon Health Industry Development Co., Ltd. (遠東宏信健康產業發展有限公司) since May 2018, and an assistant to the principal of Zhejiang Zhoushan Dinghai Guanghua Hospital of Far East Horizon Health Industry Development Co., Ltd. (遠東宏信健康產業發展有限公司) since March 2020. Mr. Wang has been the director of discipline construction of Far East Horizon Health Industry Development Co., Ltd. (遠東宏信健康產業發展有限公司) since June 2022. He has been a director of the Company since June 2020.

Mr. Wang graduated from the People's Liberation Army Air Force Military Medical University, formerly the Fourth Military Medical University (中國人民解放軍空軍軍醫大學原第四軍醫大學) with a bachelor degree of clinical medicine in July 1999 and a master degree in orthopedics in June 2007. He further obtained a doctorate degree in surgery from the Institute of orthopedics, PLA Medical College/PLA General Hospital (解放軍醫學院／解放軍總醫院) in July 2014.

Independent Non-executive Directors

Mr. Weng Jie (翁杰), aged 60, is currently the professor of Southwest Jiaotong University (西南交通大學). He is mainly responsible for the teaching, scientific research and management of the biomedical engineering. He joined Sichuan University (四川大學) as a trainee researcher in July 1983, before taking up the positions of a research assistant in November 1988 and an associate research fellow in November 1992. Afterwards, he assumed the position of a research fellow at Sichuan University in November 1996. He then joined the Nanyang Technological University (南洋理工大學) in Singapore as a research fellow in July 1999. From March 2001 to December 2001, Mr. Weng started working as an associate research fellow in Queen's University, Canada. Since March 2002, Mr. Weng has been the professor, doctoral tutor and deputy executive director (was removed from his post in November 2020 for the reason of age) of the Faculty of Medicine of Southwest Jiaotong University (西南交通大學). Mr. Weng graduated from the Sichuan University (四川大學) with a bachelor degree of science majoring in solid-state physics (固體物理) in July 1983 and a master degree in science in solid-state physics in July 1988. He then obtained a doctorate degree in biomedical engineering from the Faculty of Medicine of Leiden University in December 1995.

Mr. Wong Tak Shing (黃德盛), aged 60, has over 30 years of experience in accounting, corporate finance, personnel and administration. Mr. Wong was previously an executive director of China Ocean Fishing Holdings Limited (Stock Code: 8047) and Sing Pao Media Enterprises Limited (Stock Code: 8010), an independent non-executive director of Pa Shun International Holdings Limited (Stock Code: 0574) and China Digital Culture (Group) Limited (Stock Code: 8175), and these companies are listed on the Stock Exchange.

From March 2011 to August 2019, Mr. Wong worked for Greentech Technology International Limited with his last position as regional chief financial officer. Mr. Wong was a consultant of Chu Lung Hai, Jimmy & Co. CPA from January 2004 to April 2006. From July 1991 to April 1999, he worked for Asia Television Limited with his last position as controller personnel and administration. From January 1990 to June 1991, he worked for Jademan Enterprises Limited with his last position as accounting manager.

From January 1989 to June 1989, he was a semi-senior accountant in Deloitte Haskins & Sells (subsequently renamed as Deloitte Touche Tohmatsu) in Hong Kong. From November 1985 to January 1988, he worked in PriceWaterhouse (subsequently renamed as PriceWaterhouseCoopers) in Hong Kong as an audit assistant. Mr. Wong graduated from the University of New England, Australia in 1989 with a Diploma in Financial Management and from the University of Southampton, U.K. with a bachelor's degree of Science in the Social Sciences in Business Economics and Accounting in 1985. Mr. Wong is currently an associate member of the CPA Australia and an associate member of the Hong Kong Institute of Certified Public Accountants.

Ms. Yao Lijie (姚立杰), aged 41, is currently the professor of Beijing Jiaotong University. Since July 1997, she has been working in the Department of Accounting of School of Economics and Management of Beijing Jiaotong University (北京交通大學經濟管理學院會計系) successively as lecturer, associate professor and professor and is mainly responsible for lecturing and scientific research. Ms. Yao obtained a bachelor degree in accounting from Minzu University of China (中央民族大學) in July 2003. She then obtained a master degree in accounting and a doctorate degree in management from Tsinghua University (清華大學) in July 2005 and July 2009 respectively. She also obtained a joint training doctorate degree in accounting from University of California-Irvine in January 2009.

Ms. Yao has completed several talent training programs, such as National Tax Leading Talents (全國稅務領軍人才), International High-end Accounting Talents (國際化高端會計人才) and National High-end Accounting Talents (全國高端會計人才). She now serves as the deputy secretary-general of China Pharmaceutical Accounting Association (中國醫藥會計學會), the deputy secretary-general of Beijing Industrial Economics Association (北京產業經濟學會) and the director of China Taxation Association (中國稅務學會).

Ms. Yao has served as an independent director of Jiangsu Baoxin Technology Co., Ltd. (江蘇寶馨科技股份有限公司) (a company listed on Shenzhen Stock Exchange with the stock code of 002514) since January 2021 and an independent director of Langxin Technology Group Co., Ltd. (朗新科技集團股份有限公司) (a company listed on Shenzhen Stock Exchange with the stock code of 300682) since December 2022.

Save as disclosed above, each of the candidates of Directors confirms that (i) he/she did not hold any other directorships in any other listed public companies in the last three years; (ii) he/she has no relationship with any directors, supervisors, senior management, substantial shareholders or controlling shareholders of the Company; and (iii) he/she has no interest in the shares of the Company within the meaning of Part XV of the SFO. Save as disclosed above, the Company considers that there is no information which is discloseable nor is/was any of the above persons involved in any of the matters required to be disclosed pursuant to any of the requirements of the provisions under Rule 13.51(2) of the Listing Rules, and there is no other matters relating to the nominations of the above persons that need to be brought to the attention of the Shareholders.

SUPERVISORS

Non-employee Representative Supervisor

Mr. Zhang Jie (張杰), aged 32, is currently the manager of purchasing department of the Company. Mr. Zhang Jie joined the Company in December 2011 as the head of the trial production group of the process department (工藝部試製組長) of the Company. From October 2012 to July 2013, he worked as a numerical control turner in the workshop (車間數控車工) of the Company. From July 2013 to December 2018, he worked at the production department of the Company with his last position as a vice manager of the production department. From December 2018 to July 2021, Mr. Zhang is responsible for the procurement department and the ninth unit of the research and development department and robot intelligence center of the Company, and since December 2018 to the present, he has been the manager of purchasing department. Mr. Zhang Jie is the general manager and legal representative of Shujie Medical Technology (Suzhou) Co., Ltd. (舒捷醫療科技(蘇州)有限公司), which is a subsidiary of the Company. Mr. Zhang Jie graduated from Beijing Institute of Technology (北京理工大學) in July 2018, majoring in computer science and technology.

Save as disclosed above, the candidate for the non-employee representative supervisor confirms that (i) he did not hold any other directorships in any other listed public companies in the last three years; (ii) he has no relationship with any directors, supervisors, senior management, substantial shareholders or controlling shareholders of the Company; and (iii) he has no interest in the shares of the Company within the meaning of Part XV of the SFO.

Save as disclosed above, the Company considers that there is no information which is discloseable nor is/was any of the above persons involved in any of the matters required to be disclosed pursuant to any of the requirements of the provisions under Rule 13.51(2) of the Listing Rules, and there is no other matter relating to the nomination of the above persons that needs to be brought to the attention of the Shareholders.

* For identification purposes only

In accordance with the Hong Kong Listing Rules, this appendix serves as an explanatory statement to provide you with information reasonably necessary to enable you to make an informed decision on whether to vote for or against the special resolution to be proposed at the 2022 Annual General Meeting, the A Shareholders Class Meeting and the H Shareholders Class Meeting for the grant of the Repurchase Mandate to the Directors.

Reasons for Repurchase of H Shares

The Directors believe that the flexibility afforded by the Repurchase Mandate would be beneficial to and in the best interest of the Company and its Shareholders. Such repurchases of the H Shares may, depending on market conditions and funding arrangements at such time, lead to an enhancement of the net asset value per Share and /or earnings per Share of the Company. Such repurchases of the H Shares will only be made when the Directors believe that it will benefit the Company and its Shareholders as a whole.

Share Capital

As at the Latest Practicable Date, the total issued capital of the Company was RMB384,280,000, comprising 95,852,000 H Shares with a par value of RMB1.00 each and 288,428,000 A Shares with a par value of RMB1.00 each.

Exercise of Repurchase Mandate

Subject to the passing of the relevant special resolution set out in the notices of the 2022 Annual General Meeting and the Class Meetings, respectively, the Board will be granted the Repurchase Mandate until the earlier of (a) the conclusion of the annual general meeting of the Company for the year 2023; or (b) the date on which the authorization granted by the relevant special resolution is revoked or varied by a special resolution at the general meeting, the class meeting of the holders of H Shares and the class meeting of the holders of A Shares of the Company (the “**Relevant Period**”). The exercise of the Repurchase Mandate is subject to relevant approval(s) of and/or filings with relevant regulatory authorities as required by the laws, rules and regulations of the PRC being obtained and/or carried out.

The exercise in full of the Repurchase Mandate (on the basis of 95,852,000 H Shares in issue as at the Latest Practicable Date and no H Shares will be allotted and issued or repurchased by the Company on or prior to the date of the 2022 Annual General Meeting and the Class Meetings) would result in a maximum of 9,585,200 H Shares being repurchased by the Company during the Relevant Period, being the maximum of 10% of the total number of the H Shares in issue as at the date of passing the relevant special resolution at the 2022 Annual General Meeting and the Class Meetings.

Funding of Repurchase

In repurchasing its H Shares, the Company intends to apply funds from the Company’s internal resources (which may include capital common reserve funds and distributable profits) legally available for such purpose in accordance with the Articles of Association and the applicable laws, rules and regulations of the PRC.

The Directors consider that there may not be a material adverse impact on the working capital or on the gearing position of the Company (as compared with the position disclosed in the latest published audited accounts contained in the financial report of the Company for the year ended 31 December 2022) in the event that the Repurchase Mandate is to be exercised in full at any time during the proposed repurchase period.

Prices of H Share

The highest and lowest prices at which the H Shares have been trading on the Hong Kong Stock Exchange during the 12 calendar months preceding the Latest Practicable Date were as follows:

Month	Highest HK\$	Lowest HK\$
2022		
May	10.00	8.28
June	14.48	8.76
July	14.10	11.36
August	13.60	11.16
September	12.76	10.84
October	13.90	10.62
November	15.42	11.80
December	16.32	14.02
2023		
January	21.60	15.22
February	22.55	18.68
March	21.15	18.32
April	21.75	17.70
May (up to the Latest Practicable Date)	20.00	15.50

Shares Repurchased by the Company

No repurchase of Shares has been made by the Company during the six months prior to the Latest Practicable Date (whether on the Hong Kong Stock Exchange or other stock exchanges).

Directors' Undertakings and General Information

The Directors have undertaken to the Hong Kong Stock Exchange that, so far as the same may be applicable, they will exercise the powers of the Company to make repurchases pursuant to the proposed special resolution to approve the Repurchase Mandate in accordance with the Hong Kong Listing Rules and the applicable laws, rules and regulations of the PRC.

None of the Directors nor, to the best of their knowledge, having made all reasonable enquiries, any of their close associates (as defined in the Hong Kong Listing Rules) presently intends to sell H Shares to the Company in the event that the Repurchase Mandate is approved by the Shareholders at the 2022 Annual General Meeting and the Class Meetings, and the conditions (if any) to which the Repurchase Mandate is subject are fulfilled.

The Company has not been notified by any core connected persons (as defined in the Hong Kong Listing Rules) of the Company that they have a present intention to sell any H Shares to the Company, or that they have undertaken not to sell any H Shares held by them to the Company in the event that the Repurchase Mandate is approved by the Shareholders at the 2022 Annual General Meeting and the Class Meetings and the conditions (if any) to which the Repurchase Mandate is subject are fulfilled.

Takeovers Code and Public Float Requirement

If as a result of a share repurchase by the Company, a substantial Shareholder's proportionate interest in the voting rights of the Company increases, such increase will be treated as an acquisition for the purpose of Rule 32 of the Codes on Takeovers Code. Accordingly, a Shareholder, or a group of Shareholders acting in concert could obtain or consolidate control of the Company or become obligated to make a mandatory offer in accordance with Rules 26 and 32 of the Takeovers Code.

As at the Latest Practicable Date, to the best knowledge and belief of the Directors, Mr. Shi Chunbao ("**Mr. Shi**") and Ms. Yue Shujun ("**Ms. Yue**") were deemed to be interested in 209,133,335 A Shares and 1,155,250 H Shares (as defined in part XV of the SFO), representing approximately 54.72% of the Company's total issued capital. Mr. Shi holds 113,685,435 A Shares and 1,155,250 H Shares as the beneficial owner. Mr. Shi, as the spouse of Ms. Yue, was deemed to be interested in 95,447,900 A Shares in the Company under the SFO. Ms. Yue holds 95,447,900 A Shares as the beneficial owner. Ms. Yue, as the spouse of Mr. Shi, was deemed to be interested in 113,685,435 A Shares and 1,155,250 H Shares in the Company under the SFO. In the event that the Directors fully exercise their Repurchase Mandate, the total interests held by Mr. Shi and Ms. Yue in the Company's total issued capital will increase to approximately 56.12%, assuming that the A Shares held by Mr. Shi and Ms. Yue as at the Latest Practicable Date remain unchanged and there is no other change to the issued share capital of the Company, and such increase would not give rise to an obligation to make a mandatory general offer under the Takeovers Code. Save as aforesaid, the Directors are not aware of any consequences which would arise under the Takeovers Code as a result of any repurchase of Shares pursuant to the Repurchase Mandate.

Assuming that no Shares are issued between the Last Practicable Date and the repurchase date, the exercise of the Repurchase Mandate in whole or in part will not result in the public float being less than 25% of the Company's shares or other minimum shareholding percentage as required by the Hong Kong Stock Exchange. The Directors do not intend to make share repurchase on the Hong Kong Stock Exchange if such repurchase would result in failure to comply with the requirements under Rule 8.08 of the Hong Kong Listing Rules.

Status of Repurchased Shares

Pursuant to the Hong Kong Listing Rules, the listing status of all repurchased H Shares of the Company will be automatically cancelled and the relevant certificates of Shares will be cancelled and destroyed.

Under the PRC laws, the repurchased H Shares will be cancelled, and the amount of the Company's registered capital shall be reduced by an amount equal to the aggregate nominal value of the repurchased H Shares accordingly.

NOTICE OF 2022 ANNUAL GENERAL MEETING

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.



北京市春立正達醫療器械股份有限公司 Beijing Chunlizhengda Medical Instruments Co., Ltd.*

(A joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1858)

NOTICE OF THE 2022 ANNUAL GENERAL MEETING

Notice is hereby given that the annual general meeting for the year 2022 (the “**2022 Annual General Meeting**”) of Beijing Chunlizhengda Medical Instruments Co., Ltd.* (the “**Company**”) will be held at 2:00 p.m. on Wednesday, 28 June 2023 at No. 10 Xinmi Xi Er Road, Southern District of Tongzhou Economic Development Zone, Tongzhou District, Beijing, the PRC to consider and, if thought fit, to pass the following resolutions:

As ordinary resolutions

1. to consider and approve the proposed profit distribution plan for 2022;
2. to consider and approve the appointment of auditors (domestic and overseas) and internal control auditor for 2023;
3. to consider and approve the remuneration for the Directors of the Company for 2023;
4. to consider and approve the annual report for 2022 and its summary;
5. to consider and approve the financial report for the year 2022;
6. to consider and approve the 2022 performance report of the independent non-executive Directors;
7. to consider and approve the report of the Board of Directors for 2022;
8. to consider and approve the remuneration for Supervisors of the Company for 2023;
9. to consider and approve the report of the Board of Supervisors for 2022;
10. to consider and approve the re-election of Mr. Shi Chunbao (史春寶) as an executive director of the Company;

NOTICE OF 2022 ANNUAL GENERAL MEETING

11. to consider and approve the re-election of Ms. Yue Shujun (岳術俊) as an executive director of the Company;
12. to consider and approve the re-election of Ms. Shi Wenling (史文玲) as an executive director of the Company;
13. to consider and approve the re-election of Mr. Xie Feng Bao (解鳳寶) as an executive director of the Company;
14. to consider and approve the re-election of Mr. Wang Xin (王鑫) as a non-executive director of the Company;
15. to consider and approve the re-election of Mr. Weng Jie (翁杰) as an independent non-executive director of the Company;
16. to consider and approve the re-election of Mr. Wong Tak Shing (黃德盛) as an independent non-executive director of the Company;
17. to consider and approve the appointment of Ms. Yao Lijie (姚立杰) as an independent non-executive director of the Company; and
18. to consider and approve the re-election of Mr. Zhang Jie (張杰) as a non-employee Representative Supervisor of the Company.

As special resolution

19. to consider and approve the grant of the following general mandate to the Board to repurchase the H Shares (the “H Shares”) of the Company:

“That:

- (a) the Board be and is hereby granted a general mandate to repurchase H Shares not exceeding 10% of the total number of the H Shares as of the date when the repurchase mandate is approved at the 2022 Annual General Meeting and the class meeting of the holders of H Shares and the class meeting of the holders of A Shares of the Company in issue during the Relevant Period (as defined below) with reference to market conditions, funding arrangements and the needs of the Company and in accordance with the relevant laws and regulations, the Articles of Association, requirements of securities regulatory authorities of the places where the shares of the Company are listed and any other relevant government or regulatory authorities of the PRC;
- (b) the Board be and is hereby authorised to deal with, all matters in relation to the repurchase of H Shares, including but not limited to:
 - (i) formulating and implementing specific repurchase plan, including but not limited to repurchase price(s), number of H Shares to be repurchased, timing(s) of repurchase and period(s) of repurchase, etc;

NOTICE OF 2022 ANNUAL GENERAL MEETING

- (ii) notifying creditors and making announcement(s) in accordance with the requirements of the Company Law of the PRC, other laws and regulations and the Articles of Association;
- (iii) opening overseas stock accounts, capital accounts and carrying out relevant procedures of change in foreign exchange registration;
- (iv) carrying out relevant approval, filing and/or disclosure procedures (if necessary) in accordance with laws, regulations, the Articles of Association and requirements of the securities regulatory authorities of the places where the shares of the Company are listed and any other relevant government or regulatory authorities in the PRC;
- (v) carrying out the cancellation procedure of the repurchased H Shares, reducing the registered capital of the Company, amending the Articles of Association in relation to the total amount of share capital, share capital structure and other relevant contents and carrying out the legal registration and filing procedures in the PRC and overseas; and
- (vi) executing all documents and dealing with other matters in relation to the repurchase of H Shares.

The above general mandate will expire on the earlier of:

- (a) the conclusion of the annual general meeting of the Company for the year 2023; or
- (b) the date on which the authorization granted by the relevant special resolution is revoked or varied by a special resolution at the general meeting, the class meeting of the holders of H Shares and the class meeting of the holders of A Shares of the Company (the “**Relevant Period**”).”

By order of the Board
Beijing Chunlizhengda Medical Instruments Co., Ltd.*
Shi Wenling
Chairman

Beijing, the PRC
26 May 2023

* For identification purposes only

As at the date of this notice, the executive Directors of the Company are Mr. Shi Chunbao, Ms. Yue Shujun, Ms. Shi Wenling and Mr. Xie Feng Bao; the non-executive Director of the Company is Mr. Wang Xin; and the independent non-executive Directors of the Company are Mr. Ge Changyin, Mr. Wong Tak Shing and Mr. Weng Jie.

NOTICE OF 2022 ANNUAL GENERAL MEETING

Notes:

1. REGISTRATION OF MEMBERS

In order to be qualified to attend and vote at the 2022 Annual General Meeting, holders of H Shares whose transfers have not been registered must deposit the transfer documents together with the relevant share certificates at the office of the H Share registrar of the Company, Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong by no later than 4:30 p.m. on Wednesday, 21 June 2023.

Holders of H Shares whose names appear on the Company's register of members at the close of business on Wednesday, 21 June 2023 are entitled to attend and vote at the 2022 Annual General Meeting.

2. APPOINTMENT OF PROXY

Any Shareholder entitled to attend and vote at the 2022 Annual General Meeting is entitled to appoint one or more proxies to attend and vote at the meeting instead of him/her. A proxy need not be a Shareholder of the Company.

The instrument to appoint a proxy shall be in writing and signed by the Shareholder or of his/her attorney duly authorised in writing or, if the Shareholder is a corporate body, either executed under its common seal or signed by its legal representative, director or duly authorised attorney. If the proxy form is signed by the attorney of the Shareholder, the power of attorney or other authorisation document authorising the attorney to sign the proxy form must be notarised.

To be valid, the proxy form, together with the power of attorney or other authority (if any), shall be lodged by hand or post, to the Company's H Share registrar in Hong Kong, Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong (for holders of H Shares) not less than 24 hours before the time appointed for holding the 2022 Annual General Meeting or its adjourned meeting (as the case may be). Completion and return of the proxy form shall not preclude Shareholders from attending and voting in person at the 2022 Annual General Meeting.

3. CONTACT INFORMATION OF THE COMPANY

Contact Person: Ms. Sun Yuan
Contact Tel: (8610) 8736 1998
Contact Email: ir@clzd.com

4. PROCEDURES OF VOTING AT THE 2022 ANNUAL GENERAL MEETING

Pursuant to Rule 13.39(4) of the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited, any vote of Shareholders at the 2022 Annual General Meeting must be taken by poll.

5. OTHERS

The 2022 Annual General Meeting is expected to take half a day. Shareholders attending the 2022 Annual General Meeting (in person or by proxy) are responsible for their own transportation and accommodation fees.

Identification documents must be shown by Shareholder(s) or proxies to attend the 2022 Annual General Meeting.

Further details of the resolutions will be included in the circular to be despatched to the holders of H Shares by the Company in due course.

This notice of 2022 Annual General Meeting is despatched to the holders of H Shares only. The notice of 2022 Annual General Meeting to the holders of A Shares is separately published on the website of the Shanghai Stock Exchange (<http://www.sse.com.cn/>).

NOTICE OF THE H SHAREHOLDERS' CLASS MEETING

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.



北京市春立正達醫療器械股份有限公司
Beijing Chunlizhengda Medical Instruments Co., Ltd.*
(A joint stock limited company incorporated in the People's Republic of China with limited liability)
(Stock Code: 1858)

NOTICE OF THE H SHAREHOLDERS' CLASS MEETING

Notice is hereby given that a class meeting of the holders of H shares (the **"H Shareholders' Class Meeting"**) of Beijing Chunlizhengda Medical Instruments Co., Ltd.* (the **"Company"**) will be held at 2:00 p.m. (or the time immediately after the conclusion of the annual general meeting for the year 2022 (the **"2022 Annual General Meeting"**) and the class meeting of A shareholders of the Company held on the same date as indicated hereunder) on Wednesday, 28 June 2023 or any adjournment thereof at No. 10 Xinmi Xi Er Road, Southern District of Tongzhou Economic Development Zone, Tongzhou District, Beijing, the PRC, to consider and, if thought fit, to pass the following resolution:

As special resolution

1. to consider and approve the grant of the following general mandate to the Board to repurchase the H Shares (the **"H Shares"**) of the Company:

"That:

- (a) the Board be and is hereby granted a general mandate to repurchase H Shares not exceeding 10% of the total number of the H Shares as of the date when the repurchase mandate is approved at the 2022 Annual General Meeting and the H Shareholders' Class Meeting and the class meeting of the holders of A Shares of the Company in issue during the Relevant Period (as defined below) with reference to market conditions, funding arrangements and the needs of the Company and in accordance with the relevant laws and regulations, the Articles of Association, requirements of securities regulatory authorities of the places where the shares of the Company are listed and any other relevant government or regulatory authorities of the PRC;
- (b) the Board be and is hereby authorised to deal with, all matters in relation to the repurchase of H Shares, including but not limited to:
 - (i) formulating and implementing specific repurchase plan, including but not limited to repurchase price(s), number of H Shares to be repurchased, timing(s) of repurchase and period(s) of repurchase, etc;

NOTICE OF THE H SHAREHOLDERS' CLASS MEETING

- (ii) notifying creditors and making announcement(s) in accordance with the requirements of the Company Law of the PRC, other laws and regulations and the Articles of Association;
- (iii) opening overseas stock accounts, capital accounts and carrying out relevant procedures of change in foreign exchange registration;
- (iv) carrying out relevant approval, filing and/or disclosure procedures (if necessary) in accordance with laws, regulations, the Articles of Association and requirements of the securities regulatory authorities of the places where the shares of the Company are listed and any other relevant government or regulatory authorities in the PRC;
- (v) carrying out the cancellation procedure of the repurchased H Shares, reducing the registered capital of the Company, amending the Articles of Association in relation to the total amount of share capital, share capital structure and other relevant contents and carrying out the legal registration and filing procedures in the PRC and overseas; and
- (vi) executing all documents and dealing with other matters in relation to the repurchase of H Shares.

The above general mandate will expire on the earlier of:

- (a) the conclusion of the annual general meeting of the Company for the year 2023; or
- (b) the date on which the authorization granted by the relevant special resolution is revoked or varied by a special resolution at the general meeting, the class meeting of the holders of H Shares and the class meeting of the holders of A Shares of the Company (the “**Relevant Period**”).”

By order of the Board
Beijing Chunlizhengda Medical Instruments Co., Ltd.*
Shi Wenling
Chairman

Beijing, the PRC
26 May 2023

* For identification purposes only

As at the date of this notice, the executive Directors of the Company are Mr. Shi Chunbao, Ms. Yue Shujun, Ms. Shi Wenling and Mr. Xie Feng Bao; the non-executive Director of the Company is Mr. Wang Xin; and the independent non-executive Directors of the Company are Mr. Ge Changyin, Mr. Wong Tak Shing and Mr. Weng Jie.

NOTICE OF THE H SHAREHOLDERS' CLASS MEETING

Notes:

1. REGISTRATION OF MEMBERS

In order to be qualified to attend and vote at the H Shareholders' Class Meeting, holders of H Shares whose transfers have not been registered must deposit the transfer documents together with the relevant share certificates at the office of the H Share registrar of the Company, Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong by no later than 4:30 p.m. on Wednesday, 21 June 2023.

H Shareholders whose names appear on the Company's register of members at the close of business on Wednesday, 21 June 2023 are entitled to attend and vote at the H Shareholders' Class Meeting.

2. APPOINTMENT OF PROXY

Any H Shareholder entitled to attend and vote at the H Shareholders' Class Meeting is entitled to appoint one or more proxies to attend and vote at the meeting instead of him/her. A proxy need not be a H Shareholder of the Company.

The instrument to appoint a proxy shall be in writing and signed by the H Shareholder or of his/her attorney duly authorised in writing or, if the H Shareholder is a corporate body, either executed under its common seal or signed by its legal representative, director or duly authorised attorney. If the proxy form is signed by the attorney of the H Shareholder, the power of attorney or other authorisation document authorising the attorney to sign the proxy form must be notarised.

To be valid, the proxy form, together with the power of attorney or other authority (if any), shall be lodged by hand or post, to the Company's H Share registrar in Hong Kong, Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, not less than 24 hours before the time appointed for holding the H Shareholders' Class Meeting or its adjourned meeting (as the case may be). Completion and return of the proxy form shall not preclude H Shareholders from attending and voting in person at the H Shareholders' Class Meeting.

3. CONTACT INFORMATION OF THE COMPANY

Contact Person: Ms. Sun Yuan
Contact Tel: (8610) 8736 1998
Contact Email: ir@clzd.com

4. PROCEDURES OF VOTING AT THE H SHAREHOLDERS' CLASS MEETING

An H Shareholder or his/her/its proxy may exercise the right to vote by poll.

5. OTHERS

The H Shareholders' Class Meeting is expected to take place immediately after the 2022 Annual General Meeting and the class meeting of the holders of A Shares of the Company. H Shareholders attending the H Shareholders' Class Meeting (in person or by proxy) are responsible for their own transportation and accommodation fees.

Identification documents must be shown by shareholder(s) or proxies to attend the H Shareholders' Class Meeting.

Further details of the resolution will be included in the circular to be despatched to the holders of H Shares by the Company in due course.